



16020 Linden Ave North, Shoreline, Washington 98133, USA

## Celiac Antibody Panel

### Complete Report

**Physician:** Sample Report  
**Patient:**  
**Accession #:** 2015000000  
**Sex:** F  
**Age:** 64

**Collected:** 2015-09-15  
**Received:** 2015-09-15  
**Completed:** 2015-09-21  
**Date of Birth:**  
**Sample Type:** Serum

| Analyte                                  | Result | Indication | Reference Range (chemiluminescent units, CU) |               |          |
|--|--------|------------|--|---------------|----------|
|  |        |            | Negative                                     | Weak Positive | Positive |
| Deamidated Gliadin Peptide IgA (DGP IgA) | 7.7    | Negative   | <20  | 20 - 30       | >30      |
| Deamidated Gliadin Peptide IgG (DGP IgG) | 3.6    | Negative   | <20  | 20 - 30       | >30      |
| Tissue Transglutaminase IgA (h-TTG IgA)  | 117.6  | Positive   | <20  | 20 - 30       | >30      |
| Tissue Transglutaminase IgG (h-TTG IgG)  | <3.8   | Negative   | <20  | 20 - 30       | >30      |

<: less than reportable range.  
 >: greater than reportable range.

**Commentary** (semi-quantitative chemiluminescent Immunoassay, CIA)

The results of this test were obtained with the FDA-approved INOVA QUANTA Flash® CIA Immunoassay. Values obtained with different manufacturers' assay methods may not be used interchangeably.

Clinical sensitivity and specificity of h-TTG IgA QUANTA Flash® are reported at 94.0% and 98.1%, respectively.

Clinical sensitivity and specificity of DGP IgA QUANTA Flash® are reported at 71.4% and 100%, respectively.

Not all patients with celiac disease are positive for h-TTG IgA autoantibodies or DGP IgA antibodies. A negative result in an untreated suspect patient may be explained by selective IgA deficiency, a relatively frequent finding in this population. The presence of h-TTG IgG autoantibodies and DGP IgG antibodies can therefore aid in the patient assessment.

Clinical sensitivity of this method for h-TTG IgG autoantibodies has been shown to be 85.7% in a subset of selective IgA deficient patients.

Individuals on a gluten-free diet prior to testing may show low serological values.

Results of this assay should not be interpreted in the absence of a complete clinical history.

Confirmation of celiac disease requires small bowel biopsies demonstrating immune-mediated villous atrophy in addition to resolution of symptoms following the introduction and maintenance of a strict gluten-free diet.

This test is not intended to diagnose, treat, cure, or prevent any disease or replace the medical advice and/or treatment obtained from a qualified healthcare practitioner.

End of Report

CLIA: 5000965661

©2015 US BioTek Laboratories, Inc.  
 ph: 206.365.1256 fx: 206.363.8790 toll free 1.877.318.8728 web: www.usbiotek.com

Source and lab test service provider: HK Biotek

Enquiry

Ms Yolanda Che

Welspring

3622-1287 (after 12noon)

info@welspring.hk

room 303, keen hung commercial building,  
80 queen's road east, wanchai, hong kong